Oncology Central

Should vascular effects of newer treatments be addressed more completely?

0

For over half a century, the development of groundbreaking chemotherapeutic agents have resulted in prolonged survival outcomes and more treatment options for patients with hematologic and oncologic malignancies. In the shadow of these achievements, cardiovascular toxicities have been documented with most agents, including newer, so-called ‘targeted therapies’, which were initially considered to be have minimal cardiovascular adverse effects [1].

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.